Rwanda

Rwanda

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

10-64 year olds
Download
Value (%) Year Type Source
1.6 (1.10 - 2.20) 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
15-64 year olds
Download
Value (%) Year Type Source
2 (1.40 - 2.70) 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
National
Download
Value (%) Year Type Source
3.8 (3.07 - 4.54) 2019 Modelled IHME
3.85 (3.10 - 4.57) 2018 Modelled IHME
3.95 (3.17 - 4.72) 2017 Modelled IHME
4.18 (3.38 - 5.02) 2016 Modelled IHME
4.44 (3.62 - 5.43) 2015 Modelled IHME
4.59 (3.73 - 5.60) 2014 Modelled IHME
4.71 (3.82 - 5.73) 2013 Modelled IHME
4.82 (3.88 - 5.86) 2012 Modelled IHME
4.93 (3.93 - 6.01) 2011 Modelled IHME
5.08 (4.02 - 6.18) 2010 Modelled IHME
5.27 (4.19 - 6.42) 2009 Modelled IHME
5.52 (4.45 - 6.73) 2008 Modelled IHME
5.78 (4.74 - 7.04) 2007 Modelled IHME
6.03 (4.93 - 7.40) 2006 Modelled IHME
6.23 (5.05 - 7.71) 2005 Modelled IHME
6.41 (5.17 - 7.94) 2004 Modelled IHME
6.59 (5.29 - 8.14) 2003 Modelled IHME
6.75 (5.37 - 8.35) 2002 Modelled IHME
6.87 (5.40 - 8.51) 2001 Modelled IHME
6.91 (5.41 - 8.65) 2000 Modelled IHME
6.91 (5.44 - 8.48) 1999 Modelled IHME
6.89 (5.45 - 8.36) 1998 Modelled IHME
6.86 (5.48 - 8.20) 1997 Modelled IHME
6.83 (5.48 - 8.12) 1996 Modelled IHME
6.82 (5.48 - 8.13) 1995 Modelled IHME
6.82 (5.49 - 8.07) 1994 Modelled IHME
6.81 (5.46 - 8.07) 1993 Modelled IHME
6.8 (5.41 - 8.12) 1992 Modelled IHME
6.8 (5.41 - 8.21) 1991 Modelled IHME
6.8 (5.37 - 8.37) 1990 Modelled IHME
4.52 (2.50 - 7.74) 2015 Modelled WHO
3.4 (2.20 - 4.30) 2016 Modelled Razavi-Shearer et al, 2018
6.67 (3.82 - 11.37) 2013 Modelled Schweitzer et al, 2015
3.9 (3.83 - 3.97) 2018 Survey/reported Makuza et al, 2019
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.35 (0.26 - 0.47) 2019 Modelled IHME
0.38 (0.28 - 0.51) 2018 Modelled IHME
0.4 (0.30 - 0.53) 2017 Modelled IHME
0.41 (0.30 - 0.53) 2016 Modelled IHME
0.42 (0.30 - 0.54) 2015 Modelled IHME
0.43 (0.32 - 0.56) 2014 Modelled IHME
0.47 (0.34 - 0.60) 2013 Modelled IHME
0.51 (0.38 - 0.66) 2012 Modelled IHME
0.57 (0.42 - 0.73) 2011 Modelled IHME
0.63 (0.46 - 0.82) 2010 Modelled IHME
0.72 (0.54 - 0.94) 2009 Modelled IHME
0.87 (0.64 - 1.13) 2008 Modelled IHME
1.06 (0.77 - 1.38) 2007 Modelled IHME
1.29 (0.93 - 1.69) 2006 Modelled IHME
1.57 (1.12 - 2.08) 2005 Modelled IHME
2.13 (1.53 - 2.81) 2004 Modelled IHME
3.04 (2.21 - 4) 2003 Modelled IHME
4.03 (2.94 - 5.30) 2002 Modelled IHME
4.82 (3.50 - 6.37) 2001 Modelled IHME
5.15 (3.72 - 6.88) 2000 Modelled IHME
5.15 (3.77 - 6.83) 1999 Modelled IHME
5.13 (3.75 - 6.83) 1998 Modelled IHME
5.12 (3.74 - 6.86) 1997 Modelled IHME
5.11 (3.73 - 6.85) 1996 Modelled IHME
5.1 (3.73 - 6.98) 1995 Modelled IHME
5.09 (3.76 - 6.84) 1994 Modelled IHME
5.09 (3.77 - 6.84) 1993 Modelled IHME
5.09 (3.78 - 6.79) 1992 Modelled IHME
5.08 (3.79 - 6.69) 1991 Modelled IHME
5.08 (3.77 - 6.66) 1990 Modelled IHME
1.74 (0.86 - 3.30) 2015 Modelled WHO
Showing out of
Show more
People living with HIV (PLHIV)
Download
Value (%) Year Type Source
4.3 (4.20 - 4.40) 2016 Survey/reported Umutesi J et al, 2017
3.6 (2.30 - 4.80) 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
Showing out of
Show more
Technical notes

Number of people living with chronic HBV

National
Download
Value Year Type Source
487,712 (385,404 - 600,107) 1990 Modelled IHME
502,989 (400,139 - 607,426) 1991 Modelled IHME
460,054 (366,117 - 548,721) 1992 Modelled IHME
376,224 (301,750 - 446,017) 1993 Modelled IHME
362,902 (292,562 - 429,667) 1994 Modelled IHME
408,870 (328,486 - 487,339) 1995 Modelled IHME
476,873 (382,666 - 566,299) 1996 Modelled IHME
522,316 (417,532 - 624,669) 1997 Modelled IHME
535,823 (424,208 - 650,767) 1998 Modelled IHME
546,353 (429,980 - 670,976) 1999 Modelled IHME
558,568 (436,885 - 698,738) 2000 Modelled IHME
567,810 (446,206 - 703,872) 2001 Modelled IHME
571,978 (454,846 - 706,945) 2002 Modelled IHME
572,401 (459,203 - 706,952) 2003 Modelled IHME
569,739 (458,980 - 705,236) 2004 Modelled IHME
567,426 (459,298 - 702,161) 2005 Modelled IHME
563,438 (461,004 - 691,165) 2006 Modelled IHME
553,643 (453,636 - 674,236) 2007 Modelled IHME
540,775 (435,452 - 659,312) 2008 Modelled IHME
529,822 (421,036 - 644,957) 2009 Modelled IHME
523,757 (414,871 - 638,048) 2010 Modelled IHME
522,809 (416,280 - 637,282) 2011 Modelled IHME
524,385 (421,744 - 638,056) 2012 Modelled IHME
524,302 (424,767 - 637,459) 2013 Modelled IHME
520,481 (423,201 - 634,479) 2014 Modelled IHME
514,500 (419,587 - 628,587) 2015 Modelled IHME
496,720 (401,304 - 596,342) 2016 Modelled IHME
480,271 (385,635 - 573,685) 2017 Modelled IHME
477,881 (385,282 - 567,637) 2018 Modelled IHME
482,389 (389,270 - 576,217) 2019 Modelled IHME
400,000 (268,000 - 514,000) 2016 Modelled Razavi-Shearer et al, 2018
Showing out of
Show more

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
2.71 (1.85 - 3.78) 2019 Modelled IHME
2.79 (1.92 - 3.95) 2018 Modelled IHME
2.8 (1.95 - 3.91) 2017 Modelled IHME
2.76 (1.90 - 3.84) 2016 Modelled IHME
2.73 (1.88 - 3.80) 2015 Modelled IHME
2.8 (1.95 - 3.91) 2014 Modelled IHME
2.99 (2.08 - 4.21) 2013 Modelled IHME
3.25 (2.26 - 4.51) 2012 Modelled IHME
3.45 (2.41 - 4.78) 2011 Modelled IHME
3.56 (2.50 - 4.98) 2010 Modelled IHME
3.61 (2.55 - 4.96) 2009 Modelled IHME
3.73 (2.66 - 5.06) 2008 Modelled IHME
3.84 (2.76 - 5.23) 2007 Modelled IHME
3.99 (2.87 - 5.41) 2006 Modelled IHME
4.19 (3 - 5.73) 2005 Modelled IHME
4.39 (3.12 - 6.09) 2004 Modelled IHME
4.57 (3.21 - 6.33) 2003 Modelled IHME
4.8 (3.38 - 6.71) 2002 Modelled IHME
5.07 (3.56 - 7.18) 2001 Modelled IHME
5.42 (3.73 - 7.82) 2000 Modelled IHME
5.74 (3.86 - 8.28) 1999 Modelled IHME
5.97 (3.93 - 8.62) 1998 Modelled IHME
6.03 (3.86 - 8.64) 1997 Modelled IHME
6.11 (3.89 - 8.80) 1996 Modelled IHME
6.2 (3.95 - 8.92) 1995 Modelled IHME
6.37 (4.16 - 9.03) 1994 Modelled IHME
6.32 (4.09 - 8.93) 1993 Modelled IHME
6.14 (3.98 - 8.59) 1992 Modelled IHME
6.03 (3.99 - 8.41) 1991 Modelled IHME
5.96 (4 - 8.30) 1990 Modelled IHME
1.03 2019 Survey/reported Rwanda Biomedical Center (RBC) MCCOD Database
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
343 (235 - 480) 2019 Modelled IHME
346 (238 - 490) 2018 Modelled IHME
340 (236 - 475) 2017 Modelled IHME
328 (226 - 456) 2016 Modelled IHME
317 (218 - 440) 2015 Modelled IHME
317 (221 - 443) 2014 Modelled IHME
333 (232 - 468) 2013 Modelled IHME
354 (246 - 491) 2012 Modelled IHME
366 (256 - 507) 2011 Modelled IHME
367 (258 - 514) 2010 Modelled IHME
363 (257 - 498) 2009 Modelled IHME
365 (261 - 496) 2008 Modelled IHME
368 (264 - 501) 2007 Modelled IHME
373 (268 - 505) 2006 Modelled IHME
381 (273 - 522) 2005 Modelled IHME
390 (277 - 541) 2004 Modelled IHME
397 (279 - 550) 2003 Modelled IHME
407 (286 - 568) 2002 Modelled IHME
419 (294 - 594) 2001 Modelled IHME
438 (301 - 632) 2000 Modelled IHME
454 (305 - 655) 1999 Modelled IHME
464 (306 - 670) 1998 Modelled IHME
459 (294 - 658) 1997 Modelled IHME
426 (272 - 614) 1996 Modelled IHME
372 (237 - 534) 1995 Modelled IHME
339 (222 - 481) 1994 Modelled IHME
349 (226 - 493) 1993 Modelled IHME
415 (269 - 581) 1992 Modelled IHME
446 (295 - 622) 1991 Modelled IHME
427 (287 - 596) 1990 Modelled IHME
696 2016 Modelled WHO
134 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
28 (21 - 36) 2019 Modelled IHME
28 (21 - 36) 2018 Modelled IHME
28 (21 - 36) 2017 Modelled IHME
28 (21 - 36) 2016 Modelled IHME
28 (21 - 36) 2015 Modelled IHME
28 (21 - 36) 2014 Modelled IHME
28 (22 - 36) 2013 Modelled IHME
29 (22 - 37) 2012 Modelled IHME
29 (22 - 37) 2011 Modelled IHME
29 (22 - 37) 2010 Modelled IHME
29 (22 - 37) 2009 Modelled IHME
29 (22 - 37) 2008 Modelled IHME
29 (23 - 37) 2007 Modelled IHME
29 (23 - 37) 2006 Modelled IHME
29 (23 - 37) 2005 Modelled IHME
29 (23 - 37) 2004 Modelled IHME
30 (23 - 38) 2003 Modelled IHME
30 (23 - 38) 2002 Modelled IHME
30 (23 - 39) 2001 Modelled IHME
30 (23 - 39) 2000 Modelled IHME
30 (23 - 39) 1999 Modelled IHME
30 (23 - 39) 1998 Modelled IHME
29 (22 - 39) 1997 Modelled IHME
29 (22 - 38) 1996 Modelled IHME
29 (22 - 38) 1995 Modelled IHME
28 (21 - 37) 1994 Modelled IHME
28 (21 - 37) 1993 Modelled IHME
28 (21 - 37) 1992 Modelled IHME
28 (21 - 37) 1991 Modelled IHME
28 (21 - 37) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
98 2019 Survey/reported WHO/UNICEF
91 2020 Survey/reported WHO/UNICEF
96 2020 Survey/reported Rwanda Demographic and Health Survey 2019-20 Final Report
Showing out of
Show more
Technical notes

Proportion of persons living with HBV diagnosed

National
Download
Value (%) Year Type Source
85 2021 Survey/reported Communication with Rwanda Biomedical Center

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV mother to child transmission elimination goal
Year of HBV elimination goal
2030
National prevalence survey within the last 5 years
Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Recommendations for HBV testing of pregnant women
Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
HBV testing policy
Universal
No patient co-pays for HBsAg testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Adopted
Simplified care: No treatment co-pays
Adopted
Adult HBV vaccination policy for high-risk populations
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2024
National prevalence survey within the last 5 years
Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Not Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Less than 2 clinic visits during treatment
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Public budget line for testing and treatment

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.72 (1.39 - 2.13) 2019 Modelled IHME
1.71 (1.39 - 2.11) 2018 Modelled IHME
1.71 (1.38 - 2.11) 2017 Modelled IHME
1.7 (1.38 - 2.11) 2016 Modelled IHME
1.7 (1.37 - 2.12) 2015 Modelled IHME
1.7 (1.38 - 2.13) 2014 Modelled IHME
1.71 (1.38 - 2.13) 2013 Modelled IHME
1.72 (1.38 - 2.15) 2012 Modelled IHME
1.74 (1.39 - 2.16) 2011 Modelled IHME
1.75 (1.40 - 2.18) 2010 Modelled IHME
1.77 (1.41 - 2.20) 2009 Modelled IHME
1.79 (1.42 - 2.22) 2008 Modelled IHME
1.81 (1.45 - 2.26) 2007 Modelled IHME
1.83 (1.47 - 2.28) 2006 Modelled IHME
1.86 (1.50 - 2.31) 2005 Modelled IHME
1.89 (1.52 - 2.34) 2004 Modelled IHME
1.92 (1.55 - 2.39) 2003 Modelled IHME
1.96 (1.58 - 2.42) 2002 Modelled IHME
1.99 (1.60 - 2.47) 2001 Modelled IHME
2.02 (1.62 - 2.51) 2000 Modelled IHME
2.04 (1.65 - 2.53) 1999 Modelled IHME
2.06 (1.67 - 2.56) 1998 Modelled IHME
2.09 (1.69 - 2.60) 1997 Modelled IHME
2.1 (1.70 - 2.62) 1996 Modelled IHME
2.12 (1.71 - 2.63) 1995 Modelled IHME
2.13 (1.72 - 2.65) 1994 Modelled IHME
2.13 (1.73 - 2.66) 1993 Modelled IHME
2.14 (1.73 - 2.66) 1992 Modelled IHME
2.15 (1.73 - 2.66) 1991 Modelled IHME
2.15 (1.72 - 2.68) 1990 Modelled IHME
0.8 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
Showing out of
Show more
People living with HIV (PLHIV)
Download
Value (%) Year Type Source
1.5 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
1.46 (1.12 - 1.94) 2019 Modelled Dugan et al., 2021
Technical notes

Prevalence of anti-HCV

10-64 year olds
Download
Value (%) Year Type Source
1.1 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
15-64 year olds
Download
Value (%) Year Type Source
1.2 (0.80 - 1.60) 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
National
Download
Value (%) Year Type Source
3.1 (0.30 - 9) 2014 Modelled Riou et al, 2015
3.1 (0.30 - 12) 2017 Modelled Sonderup et al, 2017
8.86 (8.70 - 9.02) 2017 Survey/reported Umutesi J et al, 2019
Showing out of
Show more
People living with HIV (PLHIV)
Download
Value (%) Year Type Source
4.6 (4.50 - 4.70) 2016 Survey/reported Umutesi J et al, 2017
2.6 (1.30 - 3.90) 2019 Survey/reported Rwanda Population-based HIV Impact Assessment
Showing out of
Show more
Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National
Download
Value Year Type Source
154,062 (123,698 - 191,939) 1990 Modelled IHME
158,711 (127,619 - 196,779) 1991 Modelled IHME
144,763 (116,810 - 179,550) 1992 Modelled IHME
117,915 (95,381 - 146,821) 1993 Modelled IHME
113,201 (91,540 - 140,909) 1994 Modelled IHME
126,892 (102,348 - 157,684) 1995 Modelled IHME
146,834 (118,705 - 183,064) 1996 Modelled IHME
158,887 (128,514 - 197,668) 1997 Modelled IHME
160,667 (129,674 - 199,345) 1998 Modelled IHME
161,438 (130,592 - 199,862) 1999 Modelled IHME
162,920 (131,276 - 202,469) 2000 Modelled IHME
164,439 (132,566 - 204,423) 2001 Modelled IHME
165,703 (134,074 - 205,023) 2002 Modelled IHME
166,857 (134,808 - 207,186) 2003 Modelled IHME
167,826 (135,017 - 207,664) 2004 Modelled IHME
169,314 (136,204 - 209,916) 2005 Modelled IHME
171,379 (137,512 - 213,001) 2006 Modelled IHME
173,236 (138,866 - 215,966) 2007 Modelled IHME
174,988 (139,458 - 217,882) 2008 Modelled IHME
177,403 (142,011 - 221,042) 2009 Modelled IHME
180,548 (144,673 - 224,548) 2010 Modelled IHME
183,968 (147,622 - 228,469) 2011 Modelled IHME
187,466 (150,571 - 233,456) 2012 Modelled IHME
190,419 (153,384 - 237,424) 2013 Modelled IHME
193,020 (156,773 - 240,939) 2014 Modelled IHME
196,924 (159,218 - 245,560) 2015 Modelled IHME
202,116 (163,939 - 250,823) 2016 Modelled IHME
207,228 (167,350 - 256,232) 2017 Modelled IHME
212,396 (172,370 - 261,728) 2018 Modelled IHME
218,025 (176,747 - 270,799) 2019 Modelled IHME
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value Year Type Source
46,800 (36,000 - 62,000) 2019 Modelled Dugan et al., 2021

HCV-related death rate

National
Download
Value (Deaths per 100,000) Year Type Source
9.7 (6.91 - 13.50) 2019 Modelled IHME
9.57 (6.83 - 13.30) 2018 Modelled IHME
9.39 (6.68 - 12.90) 2017 Modelled IHME
9.22 (6.61 - 12.60) 2016 Modelled IHME
9.12 (6.52 - 12.40) 2015 Modelled IHME
8.95 (6.53 - 12.20) 2014 Modelled IHME
8.72 (6.47 - 11.70) 2013 Modelled IHME
8.57 (6.47 - 11.40) 2012 Modelled IHME
8.41 (6.37 - 11.10) 2011 Modelled IHME
8.37 (6.42 - 11) 2010 Modelled IHME
8.46 (6.51 - 11.10) 2009 Modelled IHME
8.68 (6.68 - 11.10) 2008 Modelled IHME
8.91 (6.94 - 11.40) 2007 Modelled IHME
9.21 (7.20 - 11.60) 2006 Modelled IHME
9.64 (7.59 - 12) 2005 Modelled IHME
10 (7.81 - 12.40) 2004 Modelled IHME
10.3 (7.89 - 12.70) 2003 Modelled IHME
10.6 (8.05 - 13.30) 2002 Modelled IHME
11 (8.22 - 13.90) 2001 Modelled IHME
11.7 (8.65 - 15.20) 2000 Modelled IHME
12.5 (9.07 - 16.30) 1999 Modelled IHME
13.3 (9.64 - 17.30) 1998 Modelled IHME
13.7 (9.70 - 17.70) 1997 Modelled IHME
14.2 (9.96 - 18.30) 1996 Modelled IHME
14.7 (10.50 - 18.90) 1995 Modelled IHME
15.5 (11.20 - 19.80) 1994 Modelled IHME
15.4 (11.10 - 19.90) 1993 Modelled IHME
14.7 (10.50 - 19) 1992 Modelled IHME
14.3 (10.20 - 18.50) 1991 Modelled IHME
14.2 (10.20 - 18.30) 1990 Modelled IHME
1.11 2019 Survey/reported Rwanda Biomedical Center (RBC) MCCOD Database
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
1,231 (877 - 1,714) 2019 Modelled IHME
1,187 (848 - 1,647) 2018 Modelled IHME
1,141 (811 - 1,566) 2017 Modelled IHME
1,095 (785 - 1,495) 2016 Modelled IHME
1,057 (756 - 1,441) 2015 Modelled IHME
1,014 (740 - 1,381) 2014 Modelled IHME
971 (720 - 1,305) 2013 Modelled IHME
933 (704 - 1,245) 2012 Modelled IHME
891 (675 - 1,181) 2011 Modelled IHME
864 (662 - 1,135) 2010 Modelled IHME
849 (654 - 1,117) 2009 Modelled IHME
850 (654 - 1,092) 2008 Modelled IHME
853 (664 - 1,090) 2007 Modelled IHME
860 (673 - 1,084) 2006 Modelled IHME
877 (690 - 1,095) 2005 Modelled IHME
888 (694 - 1,105) 2004 Modelled IHME
892 (685 - 1,106) 2003 Modelled IHME
898 (682 - 1,126) 2002 Modelled IHME
909 (680 - 1,146) 2001 Modelled IHME
948 (699 - 1,225) 2000 Modelled IHME
992 (717 - 1,291) 1999 Modelled IHME
1,033 (750 - 1,344) 1998 Modelled IHME
1,040 (738 - 1,350) 1997 Modelled IHME
988 (695 - 1,277) 1996 Modelled IHME
884 (630 - 1,135) 1995 Modelled IHME
825 (594 - 1,053) 1994 Modelled IHME
853 (612 - 1,099) 1993 Modelled IHME
995 (710 - 1,283) 1992 Modelled IHME
1,061 (758 - 1,368) 1991 Modelled IHME
1,018 (729 - 1,313) 1990 Modelled IHME
900 2016 Modelled WHO
144 2019 Survey/reported Rwanda Biomedical Center (RBC) MCCOD Database
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (14 - 28) 2019 Modelled IHME
21 (14 - 28) 2018 Modelled IHME
21 (14 - 28) 2017 Modelled IHME
21 (14 - 27) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 26) 2009 Modelled IHME
19 (14 - 26) 2008 Modelled IHME
19 (13 - 26) 2007 Modelled IHME
19 (13 - 26) 2006 Modelled IHME
19 (13 - 25) 2005 Modelled IHME
19 (13 - 25) 2004 Modelled IHME
19 (13 - 25) 2003 Modelled IHME
19 (13 - 25) 2002 Modelled IHME
19 (13 - 25) 2001 Modelled IHME
18 (13 - 25) 2000 Modelled IHME
19 (13 - 25) 1999 Modelled IHME
19 (13 - 25) 1998 Modelled IHME
19 (13 - 26) 1997 Modelled IHME
19 (13 - 26) 1996 Modelled IHME
20 (13 - 27) 1995 Modelled IHME
20 (14 - 27) 1994 Modelled IHME
20 (14 - 27) 1993 Modelled IHME
20 (13 - 27) 1992 Modelled IHME
19 (13 - 27) 1991 Modelled IHME
19 (13 - 26) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of persons treated for HCV

National
Download
Value Year Type Source
1,265 2017 Survey/reported Communication with Rwanda Biomedical Center
6,573 2018 Survey/reported Communication with Rwanda Biomedical Center
9,184 2019 Survey/reported Communication with Rwanda Biomedical Center
16,891 2020 Survey/reported Communication with Rwanda Biomedical Center
17,429 2021 Survey/reported Communication with Rwanda Biomedical Center
Showing out of
Show more
Technical notes

Cumulative number of persons treated for HCV

National
Download
Value Year Type Source
300 2015 Survey/reported WHO, 2021
1,000 2016 Survey/reported WHO, 2021
13,800 2018 Survey/reported WHO, 2021
Showing out of
Show more
National (2015-2021)
Download
Value Year Type Source
54,518 2021 Survey/reported Communication with Rwanda Biomedical Center

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016

Price of HCV cure (Average price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
510 2019 Survey/reported WHO, 2021

Price of HCV cure (Cheapest price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
60 2019 Survey/reported WHO, 2021
HBV National Action Plan
HBV elimination goal
HBV mother to child transmission elimination goal
Year of HBV elimination goal
2030
National prevalence survey within the last 5 years
Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Recommendations for HBV testing of pregnant women
Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
HBV testing policy
Universal
No patient co-pays for HBsAg testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Adopted
Simplified care: No treatment co-pays
Adopted
Adult HBV vaccination policy for high-risk populations
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2024
National prevalence survey within the last 5 years
Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Not Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Less than 2 clinic visits during treatment
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Public budget line for testing and treatment

Overview

Resources